API manufacturer Dipharma did not have the reliable data it needed to make accurate decisions, so it turned to Cortellis Generics Intelligence TM because of its reliable and independently validated product and patent intelligence. Cortellis Generics Intelligence has contributed to the growth of Dipharma’s business by: reducing the workload for generic portfolio selection, gaining insight as to when drugs can go generic, helping the organization monitor competition and saving four to five hours per week due to increased productivity. Understanding when a drug can become generic Case Study | Dipharma "[Cortellis Generics Intelligence] is one of the key starting points for identifying new potential generics and is our first choice to collect all relevant information

Join for free to read